Vandetanib plus pernetrexed versus pemetrexed as 2nd-line therapy in patients with advanced NSCLC: a randomized, double-blind phase III trial (ZEAL)

被引：0
|
作者：
de Boer, Richard H. [1 ]
Arrieta, Oscar [2 ]
Gottfried, Maya [3 ]
Blackhall, Fiona H. [4 ]
Raats, Johann [5 ]
Yang, Chih-Hsin [6 ]
Langmuir, Peter [7 ]
Milenkova, Tsveta [8 ]
Read, Jessica [8 ]
Vansteenkiste, Johan [9 ]
机构：
[1] Western Hosp, Melbourne, Vic, Australia
[2] Inst Nacl Cancerol, Mexico City, DF, Mexico
[3] Meir Med Ctr, Kefar Sava, Israel
[4] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England
[5] Panorama Med Ctr, Cape Town, South Africa
[6] Natl Taiwan Univ Hosp, Taipei, Taiwan
[7] AstraZeneca, Wilmington, DE USA
[8] AstraZeneca, Macclesfield, Cheshire, England
[9] Katholieke Univ Leuven Hosp, Leuven, Belgium
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S356 / S357
页数：2
相关论文
共 50 条
  • [1] Vandetanib plus pemetrexed vs pemetrexed as 2nd-line therapy in patients with advanced non-small-cell lung cancer (NSCLC); a randomized, double-blind phase III trial
    Vansteenkiste, J.
    Arrieta, O.
    Gottfried, M.
    Blackhall, F. H.
    Raats, J.
    Yang, C. H.
    Langmuir, P.
    Milenkova, T.
    Read, J.
    de Boer, R. H.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 506 - 506
  • [2] Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL)
    De Boer, R.
    Arrieta, O.
    Gottfried, M.
    Blackhall, F. H.
    Raats, J.
    Yang, C. H.
    Langmuir, P.
    Milenkova, T.
    Read, J.
    Vansteenkiste, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced NSCLC: a randomized, double-blind phase III trial (ZODIAC)
    Herbst, Roy S.
    Sun, Yan
    Korfee, Soenke
    Germonpre, Paul
    Saijo, Nagahiro
    Zhou, Caichun
    Wang, Jie
    Langmuir, Peter
    Tada, Hiroomi
    Kennedy, Sarah J.
    Johnson, Bruce E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S357 - S358
  • [4] Vandetanib versus erlotinib in patients with previously treated advanced NSCLC: a randomized, double-blind phase III trial (ZEST)
    Natale, Ronald B.
    Thongprasert, Sumitra
    Greco, F. Anthony
    Thomas, Michael
    Tsai, Chun-Ming
    Sunpaweravong, Patrapim
    Ferry, David
    Langmuir, Peter
    Gogov, Sven
    Rowbottom, Jacqui A.
    Goss, Glenwood D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S358 - S358
  • [5] Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial
    de Boer, Richard H.
    Arrieta, Oscar
    Yang, Chih-Hsin
    Gottfried, Maya
    Chan, Valorie
    Raats, Johann
    de Marinis, Filippo
    Abratt, Raymond P.
    Wolf, Juergen
    Blackhall, Fiona H.
    Langmuir, Peter
    Milenkova, Tsveta
    Read, Jessica
    Vansteenkiste, Johan F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (08) : 1067 - 1074
  • [6] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial
    Eberhardt, W. E. E.
    Johnson, B. E.
    Sun, Y.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Tada, H.
    Kennedy, S.
    Herbst, R. S.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 505 - 505
  • [7] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
    Herbst, R. S.
    Sun, Y.
    Korfee, S.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Langmuir, P.
    Kennedy, S. J.
    Johnson, B. E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (18)
  • [8] Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZODIAC)
    Herbst, R. S.
    Sun, Y.
    Korfee, S.
    Germonpre, P.
    Saijo, N.
    Zhou, C.
    Wang, J.
    Langmuir, P.
    Kennedy, S. J.
    Johnson, B. E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [9] Vandetanib versus erlotinib in patients with previously treated advanced non-small-cell lung cancer (NSCLC): a randomized, double-blind phase III trial
    Goss, G. D.
    Thongprasert, S.
    Greco, F. A.
    Thomas, M.
    Tsai, C. M.
    Sunpaweravong, P.
    Ferry, D.
    Gogov, S.
    Rowbottom, J. A.
    Natale, R. B.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 506 - 506
  • [10] Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
    Wells, Samuel A., Jr.
    Robinson, Bruce G.
    Gagel, Robert F.
    Dralle, Henning
    Fagin, James A.
    Santoro, Massimo
    Baudin, Eric
    Elisei, Rossella
    Jarzab, Barbara
    Vasselli, James R.
    Read, Jessica
    Langmuir, Peter
    Ryan, Anderson J.
    Schlumberger, Martin J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (02) : 134 - 141
12345